Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis

Nicolás Fissolo; Pascal Benkert; Jaume Sastre‐Garriga; Neus Mongay‐Ochoa; Andreu Vilaseca-Jolonch; Sara Llufriú; Yolanda Blanco; Harald Hegen; Klaus Berek; Francisco Pérez‐Miralles; Konrad Rejdak; Luisa María Villar; Enric Monreal; Roberto Álvarez‐Lafuente; O. Soylu; Ahmed Abdelhak; Franziska Bachhuber; Hayrettin Tumani; Sergio Martínez‐Yélamos; Antonio Sánchez; Antonio Garcı́a-Merino; Lucía Gutiérrez; Tamara Castillo‐Triviño; Jan Lycke; Igal Rosenstein; Roberto Furlan; Massimo Filippi; Nieves Téllez; Lluís Ramió‐Torrentà; Jan D. Lünemann; Heinz Wiendl; Sara Eichau; Michael Khalil; Jens Kühle; Xavier Montalbán; Manuel Comabella

doi:10.1136/jnnp-2023-332251

Related publications

Article2017

Long-term disability progression in primary progressive multiple sclerosis: a 15-year study

Maria A. Rocca, Maria Pia Sormani, Marco Rovaris, Domenico Caputo, Angelo Ghezzi, Enrico Montanari, Antonio Bertolotto, Alice Laroni, Roberto Bergamaschi, Vittorio Martinelli, Gıancarlo Comı, Massimo Filippi

Article2016

CSF β-amyloid as a putative biomarker of disease progression in multiple sclerosis

Anna M. Pietroboni, Francesca Schiano di Cola, Marta Scarioni, Chiara Fenoglio, Barbara Spanò, Andrea Arighi, Sara Cioffi, Emanuela Oldoni, Milena De Riz, Paola Basilico, Alberto Calvi, Giorgio Fumagalli, Fabio Triulzi, Daniela Galimberti, Marco Bozzali, Elio Scarpini

Article2022

Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple Sclerosis

Emilio Portaccio, Mattia Fonderico, Pietro Iaffaldano, Luisa Pastò, Lorenzo Razzolini, Angelo Bellinvia, Giovanna De Luca, Paolo Ragonese, Francesco Patti, Vincenzo Brescia Morra, Eleonora Cocco, Patrizia Sola, Matilde Inglese, Giacomo Lus, Carlo Pozzilli, Davide Maimone, Alessandra Lugaresi, Paola Gazzola, Gıancarlo Comı, Ilaria Pesci, Daniele Spitaleri, Marta Rezzonico, Marika Vianello, ,

Preprint2021

The Effects of The MTHFR 677C&gt;T (Rs1801133) Genetic Variant on Susceptibility and Disability in Multiple Sclerosis Patients are Mediated by Homocysteine But Not Folate Levels

Claudia Mara Ribeiro, Sayonara Rangel Oliveira, Tamires Flauzino, Daniela Frizon Alfieri, Andréa Name Colado Simão, Marcell Alysson Batisti Lozovoy, Michael Maes, Edna Maria Vissoci Reiche

Preprint2021

The Effects of the MTHFR 677C&gt;T (rs1801133) Genetic Variant on Susceptibility and Disability in Multiple Sclerosis Patients are Mediated by Homocysteine but not Folate Levels

Claudia Mara Ribeiro, Sayonara Rangel Oliveira, Tamires Flauzino, Daniela Frizon Alfieri, Andréa Name Colado Simão, Marcell Alysson Batisti Lozovoy, Michael Maes, Edna Maria Vissoci Reiche

Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis

Abstract

Discussion(0)

Related publications

Long-term disability progression in primary progressive multiple sclerosis: a 15-year study

CSF β-amyloid as a putative biomarker of disease progression in multiple sclerosis

Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple Sclerosis

The Effects of The MTHFR 677C&gt;T (Rs1801133) Genetic Variant on Susceptibility and Disability in Multiple Sclerosis Patients are Mediated by Homocysteine But Not Folate Levels

The Effects of the MTHFR 677C&gt;T (rs1801133) Genetic Variant on Susceptibility and Disability in Multiple Sclerosis Patients are Mediated by Homocysteine but not Folate Levels

Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis

Abstract

Discussion(0)

Related publications

Long-term disability progression in primary progressive multiple sclerosis: a 15-year study

CSF β-amyloid as a putative biomarker of disease progression in multiple sclerosis

Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple Sclerosis

The Effects of The MTHFR 677C&amp;gt;T (Rs1801133) Genetic Variant on Susceptibility and Disability in Multiple Sclerosis Patients are Mediated by Homocysteine But Not Folate Levels

The Effects of the MTHFR 677C&amp;gt;T (rs1801133) Genetic Variant on Susceptibility and Disability in Multiple Sclerosis Patients are Mediated by Homocysteine but not Folate Levels

The Effects of The MTHFR 677C>T (Rs1801133) Genetic Variant on Susceptibility and Disability in Multiple Sclerosis Patients are Mediated by Homocysteine But Not Folate Levels

The Effects of the MTHFR 677C>T (rs1801133) Genetic Variant on Susceptibility and Disability in Multiple Sclerosis Patients are Mediated by Homocysteine but not Folate Levels